Generating and managing Intellectual Property (IP) is a priority and strong competency at Lumeda, in which the two company founders are inventors on over 85 issued patents with numerous patents pending.

Our DigiLum™ product is protected under an IP portfolio that includes both internally generated and externally licensed IP. Lumeda has secured a globally exclusive license to patents from Roswell Park Cancer Institute covering novel medical devices and light dosimetry methods.

The company has generated 28 invention disclosures of which 13 have been processed into patent applications with recent patents granted that cover optical devices, instrumentation, and machine-learning algorithms incorporated in the DigiLum™ system, as well as use of the system in minimally invasive procedures and other settings.